Frontline Perspectives on Buprenorphine for the Management of Chronic Pain
DOI: https://doi.org/10.2147/jmdh.s449748
2024-03-27
Journal of Multidisciplinary Healthcare
Abstract:Jeremy Adler, 1 Theresa Mallick-Searle, 2 Mark Garofoli, 3 Amanda Zimmerman 4 1 Pacific Pain Medicine Consultants, Encinitas, CA, USA; 2 Division of Pain Medicine, Stanford Health Care, Redwood City, CA, USA; 3 West Virginia University School of Pharmacy, Morgantown, WV, USA; 4 West Forsyth Pain Management, Winston-Salem, NC, USA Correspondence: Jeremy Adler, Pacific Pain Medicine Consultants, 477 N. El Camino Real, Ste B301, Encinitas, CA, 92024, USA, Email Due to the prevalence of chronic pain and high-impact chronic pain in the US, a significant percentage of the population is prescribed opioids for pain management. However, opioid use disorder is associated with reduced quality of life, along with fatal opioid overdoses, and is a significant burden on the US economy. Considering the clinical needs of patients with intractable chronic pain and the potential harms associated with prescribed and illicit opioids in our communities, having a deep understanding of current treatment options, supporting evidence, and clinical practice guidelines is essential for optimizing treatment selections. Buprenorphine is a Schedule III opioid with a unique mechanism of action, allowing effective and long-lasting analgesia at microgram doses with fewer negative side effects and adverse events, including respiratory depression, when compared with other immediate-release, long-acting, and extended-release prescription opioids. Due to its relatively lower risk for overdose and misuse, buprenorphine was recently added to the Clinical Practice Guideline for the Use of Opioids in the Management of Chronic Pain as a first-line treatment for chronic pain managed by opioids by the US Departments of Defense and Veterans Affairs, and the Department of Health and Human Services recommends that buprenorphine be made available for the treatment of chronic pain. In this narrative review, we discuss the different buprenorphine formulations, clinical efficacy, advantages for older adults and other special populations, clinical practice guideline recommendations, and payer considerations of buprenorphine and suggest that buprenorphine products approved for chronic pain should be considered as a first-line treatment for this indication. Keywords: opioid analgesics, partial opioid agonists, opioid crisis, chronic pain In 2021, more than 106,000 Americans died of drug-involved overdoses. Overdose deaths involving prescription or illicitly manufactured synthetic opioids other than methadone (primarily illicit fentanyl) rose to 70,601 in 2021, whereas 16,706 deaths involved prescribable opioids, many of which were found in combination with fentanyl. 1 The US economic cost of opioid use disorder (OUD) and fatal opioid overdoses reached nearly $1.5 trillion in 2020 primarily due to reduced quality of life from OUD and the value of life lost due to fatal overdose. 2,3 Due to the high prevalence of chronic pain and high-impact chronic pain in the US, 4 a significant percentage of the population is still prescribed opioids for pain management. Considering both the clinical needs of patients with intractable chronic pain and the potential harms associated with prescribed and illicit opioids in our communities, having a deep understanding of current treatment options, supporting evidence, and clinical practice guidelines is essential for optimizing treatment selections. Here, we present a narrative review of the different buprenorphine formulations, clinical efficacy, advantages for older adults and other special populations, and payer considerations of buprenorphine based on the relevant studies identified from PubMed and recent clinical practice guideline recommendations. Buprenorphine is a partial agonist opioid available in different formulations and doses used in patients who have pain (microgram dosing), OUD (milligram dosing), or both. Since the research of analgesic pharmacology has broadened, when an opioid is medically indicated, buprenorphine may be considered as first-line therapy for chronic pain that cannot be adequately managed with non-opioid analgesics. 5 Buprenorphine formulations include sublingual tablet, buccal film, intravenous, subcutaneous (injection and implant), and patch (Table 1). Buprenorphine buccal film (BBF, Belbuca ® ) and the buprenorphine transdermal patch (Butrans ® ), Schedule III opioids, are currently indicated specifically for long-term pain management for which non-opioid alternative treatments are inadequate. 6,7 Table 1 Approved Buprenorphine Products and Dosage Strengths Unlike most naturally occurring, semi-synthetic, and synthetic opioids, which are Schedule II full μ-opioid receptor agonists, buprenorphine exerts a unique multimechani -Abstract Truncated-
health care sciences & services